Mathias Hänel

10.3k total citations
72 papers, 1.8k citations indexed

About

Mathias Hänel is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Mathias Hänel has authored 72 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 29 papers in Oncology and 21 papers in Pathology and Forensic Medicine. Recurrent topics in Mathias Hänel's work include Multiple Myeloma Research and Treatments (21 papers), Acute Myeloid Leukemia Research (20 papers) and Lymphoma Diagnosis and Treatment (20 papers). Mathias Hänel is often cited by papers focused on Multiple Myeloma Research and Treatments (21 papers), Acute Myeloid Leukemia Research (20 papers) and Lymphoma Diagnosis and Treatment (20 papers). Mathias Hänel collaborates with scholars based in Germany, United States and France. Mathias Hänel's co-authors include Gerhard Ehninger, Michael Pfreundschuh, Markus Löffler, Norbert Schmitz, Lorenz Trümper, Niels Murawski, Gerhard Held, Markus Schaich, Martin Bornhäuser and Hans–Konrad Müller–Hermelink and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mathias Hänel

64 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mathias Hänel Germany	21	814	734	675	484	355	72	1.8k
Ho‐Jin Shin South Korea	22	691 0.8×	944 1.3×	655 1.0×	365 0.8×	222 0.6×	182	2.0k
Muhıt Özcan Türkiye	21	697 0.9×	673 0.9×	944 1.4×	360 0.7×	168 0.5×	174	2.0k
J. O. Armitage United States	20	1.4k 1.8×	588 0.8×	1.1k 1.6×	613 1.3×	383 1.1×	54	2.5k
R. E. Marcus United Kingdom	18	1.1k 1.4×	514 0.7×	979 1.5×	640 1.3×	223 0.6×	47	1.9k
Dominic Culligan United Kingdom	26	929 1.1×	1.0k 1.4×	767 1.1×	504 1.0×	290 0.8×	75	2.9k
David Westerman Australia	27	1.4k 1.7×	732 1.0×	776 1.1×	1.4k 3.0×	223 0.6×	125	2.8k
Edward Agura United States	22	1.0k 1.3×	1.6k 2.2×	1.1k 1.6×	662 1.4×	229 0.6×	49	2.9k
Hannes Wandt Germany	22	1.2k 1.5×	1.0k 1.4×	1.1k 1.6×	785 1.6×	157 0.4×	57	2.6k
Anne Sonet Belgium	22	1.3k 1.6×	265 0.4×	873 1.3×	589 1.2×	396 1.1×	64	2.2k
Tak Takvorian United States	27	1.5k 1.9×	957 1.3×	1.1k 1.6×	899 1.9×	529 1.5×	58	2.9k

Countries citing papers authored by Mathias Hänel

Since Specialization

Citations

This map shows the geographic impact of Mathias Hänel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathias Hänel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathias Hänel more than expected).

Fields of papers citing papers by Mathias Hänel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathias Hänel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathias Hänel. The network helps show where Mathias Hänel may publish in the future.

Co-authorship network of co-authors of Mathias Hänel

This figure shows the co-authorship network connecting the top 25 collaborators of Mathias Hänel. A scholar is included among the top collaborators of Mathias Hänel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathias Hänel. Mathias Hänel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stasik, Sebastian, Jan‐Niklas Eckardt, Christoph Röllig, et al.. (2025). The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML. British Journal of Haematology. 206(5). 1373–1379.

Tresckow, Bastian von, Hans Christian Reinhardt, Christian Jehn, et al.. (2024). How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective. Frontiers in Oncology. 14. 1466803–1466803. 1 indexed citations

Beck, Susanne, Vladimı́r Beneš, Hans Salwender, et al.. (2023). RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. Frontiers in Immunology. 14. 1286700–1286700. 3 indexed citations

Sockel, Katja, Friedrich Stölzel, Christoph Röllig, et al.. (2022). Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse. SHILAP Revista de lepidopterología. 3 indexed citations

Shouval, Roni, Myriam Labopin, David Bomze, et al.. (2020). Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplantation. 55(12). 2244–2253. 6 indexed citations

Kriegsmann, Katharina, Jens Hillengaß, Marc S. Raab, et al.. (2018). The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. OncoImmunology. 7(10). e1486356–e1486356. 15 indexed citations

Thiel, Andreas, Johannes Schetelig, Wolfram Pönisch, et al.. (2015). Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Annals of Oncology. 26(7). 1434–1440. 7 indexed citations

Pfreundschuh, Michael, Viola Poeschel, Samira Zeynalova, et al.. (2014). Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Journal of Clinical Oncology. 32(36). 4127–4133. 59 indexed citations

Murawski, Niels, Michael Pfreundschuh, Samira Zeynalova, et al.. (2014). Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Annals of Oncology. 25(9). 1800–1806. 48 indexed citations

10.

Gessi, Marco, K. Kuchelmeister, Udo Kellner, et al.. (2012). Unusual clinico-pathological features in primary Hodgkin’s lymphomas of the central nervous system. Acta Neurochirurgica. 155(1). 19–24. 8 indexed citations

11.

Engert, Andreas, Volker Diehl, Jeremy Franklin, et al.. (2009). Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study. Journal of Clinical Oncology. 27(27). 4548–4554. 303 indexed citations

12.

Zwick, Carsten, Josef Birkmann, Norma Peter, et al.. (2008). Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Annals of Hematology. 87(9). 717–726. 5 indexed citations

13.

Platzbecker, Uwe, Christian Thiede, Monika Füssel, et al.. (2006). Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia. 20(4). 707–714. 45 indexed citations

14.

Hiddemann, Wolfgang, Roswitha Forstpointner, Martin Dreyling, et al.. (2005). Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).. Blood. 106(11). 920–920. 6 indexed citations

15.

Bornhäuser, Martin, Mathias Hänel, Markus Schaich, et al.. (2005). Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission. Bone Marrow Transplantation. 36(12). 1083–1088. 3 indexed citations

16.

Naumann, Ralph, Bettina Beuthien‐Baumann, Jan Schulze, et al.. (2004). Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. British Journal of Cancer. 90(3). 620–625. 106 indexed citations

17.

Haisch, A., M. Bücheler, Mathias Hänel, et al.. (2004). Tissue engineered composite grafts (cartilage, keratinocytes, mucosa) for head and neck surgery. Technology and Health Care. 12(2). 159–160.

18.

Kroschinsky, Frank, Katrin Friedrich, Mathias Hänel, et al.. (2003). Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma. Annals of Hematology. 82(1). 47–52. 7 indexed citations

19.

Kroschinsky, Frank, Martin Bornhäuser, Rainer Ordemann, et al.. (2002). Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. Transplant Infectious Disease. 4(3). 132–136. 9 indexed citations

20.

Hänel, Mathias, Nicolaus Kröger, Frank Kroschinsky, et al.. (2001). Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. Journal of Cancer Research and Clinical Oncology. 127(6). 387–395. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact